Ionosite - Surgical Site Infection Clinical Pipeline
SSIs represent a significant burden in terms of patient morbidity and mortality, and add significant costs to health systems and service payers worldwide (49). CDC has reported costs of $5 billion, but estimates elsewhere in the literature have reached as high as $29 billion per year (48).
IonoSite™ has promise as a means to help reduce the risk of - or treat - SSI. Evidence includes:
-
Nitric Oxide’s antimicrobial properties (4-8)
-
Evidence suggesting that Origin’s technology can facilitate NO-penetration into tissue (47)
-
Evidence from the “Plason’’ plasma device (a precursor device based on core IonoJet™ technology). The Plason has been used to treat more than 10,000 patients with a wide variety of skin wounds and other disorders The patient group included individuals with complicated, protracted post-operative wounds. The treatment markedly accelerated the healing process throughout this group. (50)